Liver stiffness in hepatocellular carcinoma and chronic hepatitis patients: Hepatitis B virus infection and transaminases should be considered

doi:10.4254/wjh.v16.i7.1018

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 7

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1416)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-4) series.

Item

Count

PDF

HTML

1001

Figures (1-3)

129

Tables (1-4)

104

Sum=1267

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=117

Jul 27, 2024 (publication date) through Nov 28, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Hepatol. Jul 27, 2024; 16(7): 1018-1028
Published online Jul 27, 2024. doi: 10.4254/wjh.v16.i7.1018

Table 1 Patient characteristics, n (%)

Characteristics	Total, 284 patients	Pos group, 200 patients	Neg group, 84 patients	P value
Age, year	53.26 ± 11.40	52.59 ± 11.17	55.35 ± 11.88	0.054
Male	259 (91.2)	180 (90.0)	79 (94.0)	0.272
BMI, kg/m²	22.64 ± 2.93	22.51 ± 2.96	22.95 ± 2.87	0.289
Diabetes	22 (7.7)	16 (8.0)	6 (7.1)	0.805
Hypertension	48 (16.8)	33 (16.5)	15 (17.9)	0.781
PLT, ×10⁹/L	185.00 (32.00-454.00)	197.00 (40.00-427.00)	155.50 (32.00-454.00)	< 0.001^b
PT, s	12.05 (9.60-16.10)	12.00 (9.60-14.90)	12.15 (10.20-16.10)	0.808
INR	1.03 (0.82-1.40)	1.03 (0.82-1.29)	1.04 (0.88-1.40)	0.861
ALB, g/L	37.80 (25.10-65.50)	37.40 (27.2-47.9)	39.45 (25.10-65.50)	0.026^a
TBIL, mol/L	13.60 (5.10-83.30)	13.40 (5.10-83.30)	13.95 (5.10-42.70)	0.559
ALT, U/L	33.00 (7.00-468.00)	35.00 (7.00-468.00)	26.00 (8.00-155.00)	< 0.001^b
AST, U/L	37.00 (12.90-438.00)	39.50 (18.00-438.00)	30.50 (12.90-209.00)	< 0.001^b
GGT, U/L	59.00 (12.00-951.00)	66.00 (12.00-951.00)	47.00 (13.00-705.00)	0.008^b
CHE, U/L	6180.00 (1141.00-20174.00)	6030.00 (1141.00-20174.00)	6682.00 (2024.00-10368.00)	0.496
CREA, μmol/L	80.00 (3.00-371.00)	78.00 (3.00-280.00)	85.00 (46.00-371.00)	< 0.001^b
AFP, μg/L	45.26 (0.00-1.14 × 10⁶)	53.92 (0.00-1.14 × 10⁶)	22.91 (0.00-927002.45)	0.008^b
¹HBV-DNA, IU/mL	3360.00 (0.00-3.53 × 10⁷)	46300.00 (101.00-3.53 × 10⁷)	0.00 (0.00-88.80)	< 0.001^b
CP score of 5/6/7/8	205/52/21/6 (72.2/18.3/7.4/2.1)	145/39/14/2 (72.5/19.5/7.0/1.0)	60/13/7/4 (71.4/15.5/8.3/4.8)	0.200
CP grade A (vs B)	257 (90.5)	184 (92.0)	73 (86.9)	0.182
ALBI score	-2.48 [(-4.77)-(-1.14)]	-2.45 [(-3.33)-(-1.61)]	-2.55 [(-4.77)-(-1.14)]	0.036^a
ALBI grade 1/2/3	104/179/1 (36.6/63.0/0.4)	66/134/0 (33.0/67.0/0.0)	38/45/1 (45.2/53.6/1.2)	0.039^a
MELD score	4.87 [(-26.65)-18.60]	4.55 [(-26.65)-18.60]	5.85 [(-2.87)-17.80]	0.001^b
FIB-4	0.70 (0.12-9.29)	0.62 (0.12-4.23)	0.87 (0.17-9.29)	0.001^b
Antiviral treatment	97 (34.2)	43 (21.5)	54 (64.3)	< 0.001^b
Pathological cirrhosis yes/no/censored	85/168/31 (29.9/59.2/10.9)	53/62.5/11.0 (26.5/62.5/11.0)	32/43/9 (38.1/51.2/10.7)	0.047^a
Single/multiple HCC lesion(s)	209/75 (73.6/26.4)	142/58 (71.0/29.0)	67/17 (79.8/20.2)	0.125
Diameter of HCC lesion, cm	5.75 (0.70-21.60)	6.25 (0.70-21.60)	4.00 (1.10-18.00)	< 0.001^b
Splenomegaly	67 (23.6)	44 (22.0)	23 (27.4)	0.330
Absent/slight/moderate or abundant ascites	264/18/2 (93.0/6.3/0.7)	187/12/1 (93.5/6.0/0.5)	77/6/1 (91.7/7.1/1.2)	0.762
Esophagogastric varices	30 (10.6)	14 (7.0)	16 (19.0)	0.003^b
BCLC stage 0/A/B	11/203/70 (3.9/71.5/24.6)	6/138/56 (3.0/69.0/28.0)	5/65/14 (6.0/77.4/16.7)	0.082
²Emin, kPa	7.90 (1.00-28.30)	8.00 (1.00-25.10)	7.50 (4.00-33.90)	0.809
²Emean, kPa	9.65 (1.00-33.90)	9.70 (1.00-31.50)	9.15 (4.00-33.90)	0.453
²Emax, kPa	12.00 (1.00-46.70)	12.10 (1.00-38.00)	11.45 (5.50-46.70)	0.536

¹Patients’ HBV-DNA was recorded as 0 when it was < 100.00 IU/mL.

²Emin, Emean, and Emax were recorded as the median values of the minimum, mean, and maximum in the five liver stiffness measurements.

^aP < 0.05.

^bP < 0.01. AFP: Alpha-fetoprotein; ALB: Albumin; ALBI: Albumin-bilirubin; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; BCLC: Barcelona clinic liver cancer; BMI: Body mass index; CHE: Choline esterase; CP: Child-Pugh; CREA: Serum creatinine; Emax: Maximum of liver stiffness; Emean: Mean of liver stiffness; Emin: Minimum of liver stiffness; FIB-4: Fibrosis-4 score; GGT: Gamma-glutamyl transpeptidase; HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma; INR: International normalized ratio; MELD: Model for end-stage liver disease; Neg group: HBV-DNA negative group; PLT: Platelet; Pos group: HBV-DNA positive group; PT: Prothrombin time; TBIL: Total bilirubin.

Table 2 Correlation between Emean with liver condition related index and liver enzymes

Parameter	Total		Pos group		Neg group
	r	P value	r	P value	r	P value
CP score	0.25	< 0.001^b	0.25	< 0.001^b	0.24	0.026^a
CP grade	0.21	< 0.001^b	0.23	0.001^b	0.18	0.106
ALBI score	0.31	< 0.001^b	0.35	< 0.001^b	0.27	0.012^a
ALBI grade	0.26	< 0.001^b	0.24	< 0.001^b	0.28	0.011^a
MELD	< 0.01	0.955	-0.06	0.432	0.11	0.308
TBIL	0.18	0.002^b	0.17	0.016^a	0.23	0.038^a
ALB	-0.25	< 0.001^b	-0.27	< 0.001^b	-0.23	0.038^a
PT	0.33	<0.001^b	0.39	< 0.001^b	0.23	0.033^a
ALT	0.12	0.042^a	0.16	0.023^a	0.08	0.447
AST	0.19	0.002^b	0.24	0.001^b	0.14	0.205
ALP	0.26	< 0.001^b	0.36	< 0.001^b	0.08	0.447

^aP < 0.05.

^bP < 0.01. ALB: Albumin; ALBI: Albumin-bilirubin; ALP: Alkaline phosphatase; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; CP: Child-Pugh; MELD: Model for end-stage liver disease; Neg group: HBV-DNA negative group; Pos group: HBV-DNA positive group; PT: Prothrombin time; TBIL: Total bilirubin.

Table 3 Correlation between Emean and liver condition with different alanine aminotransferase

Parameter	Pos group				Neg group
	ALT ≤ 40 U/L, n = 122		ALT > 40 U/L, n = 78		ALT ≤ 40 U/L, n = 71		ALT > 40 U/L, n = 13
	r	P value	r	P value	r	P value	r	P value
CP score	0.22	0.016^a	0.23	0.044^a	0.31	0.009^b	0.23	0.447
CP grade	0.2	0.030^a	0.21	0.065	0.2	0.102	0.23	0.447
ALBI score	0.29	0.001^b	0.36	0.001^b	0.35	0.003^b	0.06	0.855
ALBI grade	0.21	0.018^a	0.27	0.018^a	0.23	0.054	0.39	0.182
MELD	-0.06	0.508	-0.08	0.48	0.18	0.125	0.02	0.945
TBIL	0.14	0.127	0.13	0.264	0.25	0.036^a	0.09	0.779
ALB	-0.24	0.007^b	-0.29	0.009^b	-0.29	0.015^a	-0.1	0.817
PT	0.43	< 0.001^b	0.33	0.004^b	0.28	0.018^a	0.07	0.811

^aP < 0.05.

^bP < 0.01. ALB: Albumin; ALBI: Albumin-bilirubin; MELD: Model for end-stage liver disease; ALT: Alanine aminotransferase; CP: Child-Pugh; HBV: Hepatitis B virus; Neg group: HBV-DNA negative group; Pos group: HBV-DNA positive group; PT: Prothrombin time; TBIL: Total bilirubin.

Table 4 Correlation between Emean and liver condition with different aspartate aminotransferase

Parameter	Pos group				Neg group
	AST ≤ 37 U/L, n = 92		AST > 37 U/L, n = 108		AST ≤ 37 U/L, n = 61		AST > 37 U/L, n = 23
	r	P value	r	P value	r	P value	r	P value
CP score	0.06	0.575	0.29	0.002^b	0.15	0.252	0.3	0.161
CP grade	0.08	0.445	0.24	0.013^a	0.07	0.612	0.22	0.321
ALBI score	0.18	0.087	0.33	< 0.001^b	0.19	0.135	0.28	0.200
ALBI grade	0.09	0.401	0.23	0.018^a	0.18	0.177	0.41	0.055
MELD	0.08	0.428	-0.1	0.321	0.04	0.783	0.25	0.244
TBIL	0.07	0.51	0.08	0.442	0.15	0.247	0.15	0.485
ALB	-0.13	0.207	-0.31	0.001^b	-0.16	0.211	-0.26	0.228
PT	0.27	0.009^b	0.35	< 0.001^b	0.17	0.186	0.19	0.380

^aP < 0.05.

^bP < 0.01. ALB: Albumin; ALBI: Albumin-bilirubin; ALT: Alanine aminotransferase; CP: Child-Pugh; HBV: Hepatitis B virus; Pos group: HBV-DNA positive group; MELD: Model for end-stage liver disease; Neg group: HBV-DNA negative group; PT: Prothrombin time; TBIL: Total bilirubin.

Citation: Huang JY, Peng JY, Long HY, Zhong X, Xie YH, Yao L, Xie XY, Lin MX. Liver stiffness in hepatocellular carcinoma and chronic hepatitis patients: Hepatitis B virus infection and transaminases should be considered. World J Hepatol 2024; 16(7): 1018-1028
URL: https://www.wjgnet.com/1948-5182/full/v16/i7/1018.htm
DOI: https://dx.doi.org/10.4254/wjh.v16.i7.1018